These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 32509577)
21. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study. Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421 [TBL] [Abstract][Full Text] [Related]
22. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer. Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237 [TBL] [Abstract][Full Text] [Related]
23. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289 [TBL] [Abstract][Full Text] [Related]
25. Detection of bladder cancer using urinary cell-free DNA and cellular DNA. Ou Z; Li K; Yang T; Dai Y; Chandra M; Ning J; Wang Y; Xu R; Gao T; Xie Y; He Q; Li Y; Lu Q; Wang L; Song Z Clin Transl Med; 2020 Jan; 9(1):4. PubMed ID: 31938901 [TBL] [Abstract][Full Text] [Related]
26. UBC®Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population. Zang Z; Kesavan NR; Esuvaranathan K Urol Int; 2023; 107(1):29-34. PubMed ID: 36273445 [TBL] [Abstract][Full Text] [Related]
27. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Roggisch J; Ecke T; Koch S Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529 [TBL] [Abstract][Full Text] [Related]
28. Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR. Tan D; Jiang W; Hu R; Li Z; Ou T Cancer Med; 2023 May; 12(10):11503-11512. PubMed ID: 37081791 [TBL] [Abstract][Full Text] [Related]
29. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000 [TBL] [Abstract][Full Text] [Related]
31. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800 [TBL] [Abstract][Full Text] [Related]
32. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924 [TBL] [Abstract][Full Text] [Related]
33. Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Pritchard JJG; Hamilton G; Hurst CD; Fraser S; Orange C; Knowles MA; Jones RJ; Leung HY; Iwata T Urol Oncol; 2020 Sep; 38(9):737.e1-737.e10. PubMed ID: 32532529 [TBL] [Abstract][Full Text] [Related]
34. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136 [TBL] [Abstract][Full Text] [Related]
35. A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine. Zhao C; Pan Y; Wang Y; Li Y; Han W; Lu L; Tang W; Li P; Ou Z; Zhang M; Xiong Z; Xu R; Lu Q; Xu Z; Qi L; Wang L; Xu G Transl Androl Urol; 2020 Jun; 9(3):1222-1231. PubMed ID: 32676405 [TBL] [Abstract][Full Text] [Related]
36. Advances in Detecting Low Prevalence Somatic da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Dimashkieh H; Wolff DJ; Smith TM; Houser PM; Nietert PJ; Yang J Cancer Cytopathol; 2013 Oct; 121(10):591-7. PubMed ID: 23801650 [TBL] [Abstract][Full Text] [Related]
39. Regulatory region mutations of Xing X; Yuan X; Liu T; Dai M; Fan Y; Liu C; Strååt K; Björkholm M; Xu D J Cancer; 2021; 12(13):3853-3861. PubMed ID: 34093793 [No Abstract] [Full Text] [Related]
40. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Cheng L; Zhang S; Wang M; Lopez-Beltran A Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]